UBS Group’s Aldeyra Therapeutics ALDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-20,000
Closed -$80K – 10186
2021
Q4
$80K Buy
+20,000
New +$153K ﹤0.01% 6500

Other funds holding ALDX

UBS Group's ALDX Position: Q3 2026 in Review

UBS Group reduced its Aldeyra Therapeutics (ALDX) stake by 99% in Q3 2026, selling an estimated $476K and leaving 3,820 shares worth $4.7K. The position accounts for ﹤0.01% of the portfolio, ranked #9634.

UBS Group first reported a position in ALDX in Q1 2015 and has held it in 44 quarters since. The position peaked at $4.27M in Q1 2022. 96 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.

  • UBS Group held 3,820 shares of Aldeyra Therapeutics worth $4.7K as of Q3 2026.
  • UBS Group sold 298,120 Aldeyra Therapeutics shares in Q3 2026, an estimated $476K.
  • Aldeyra Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #9634 holding.
  • UBS Group first reported a position in Aldeyra Therapeutics in Q1 2015 and has held it in 44 quarters since.
  • UBS Group's Aldeyra Therapeutics position peaked at $4.27M in Q1 2022.
  • 96 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.